Papillary serous carcinoma of the uterus: Increased risk of subsequent or concurrent development of breast carcinoma

被引:29
作者
Geisler, JP [1 ]
Sorosky, JI [1 ]
Duong, HL [1 ]
Buekers, TE [1 ]
Geisler, MJ [1 ]
Sood, AK [1 ]
Anderson, B [1 ]
Buller, RE [1 ]
机构
[1] Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Div Gynecol Oncol, Iowa City, IA 52242 USA
关键词
serous carcinoma; endometrial carcinoma; breast carcinoma;
D O I
10.1006/gyno.2001.6445
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Some women with endometrial cancer may at increased risk for developing breast cancer. The histologic type of endometrial cancer associated with synchronous or subsequent breast cancer has not been clearly established. Our purpose was to determine if a certain histologic type of endometrial cancer was associated with an increased risk of synchronous or subsequent breast cancer. Methods. The University of Iowa Hospitals and Clinics tumor registry was queried to ascertain all patients with the diagnosis of uterine cancer from January 1, 1983, to December 31, 1994. Statistics were performed utilizing SPSS for Windows version 9.0 (SPSS Inc., Chicago, IL), including Student's t tests and X-2 tests. Results. Five hundred ninety-two patients had endometrial adenocarcinoma during the study period. Five hundred thirty-six women had endometrioid adenocarcinoma, 23 women had papillary serous carcinoma (UPSC), 21 women had adenosquamous carcinoma, 10 women had clear-cell carcinoma, and 1 woman each had mucinous or squamous carcinoma. Twelve patients had previously been diagnosed with breast carcinomas. Twenty-five patients were diagnosed with breast cancer either concurrently or subsequent to their diagnosis of endometrial cancer. Synchronous or subsequent breast cancers developed in 3.2% of patients with endometrioid carcinoma and in 25% of patients with UPSC (P < 0.001). Conclusion. Patients with UPSC have an increased risk of development of breast cancer as compared to patients with endometrioid adenocarcinoma of the uterus. (C) 2001 Academic Press.
引用
收藏
页码:501 / 503
页数:3
相关论文
共 20 条
[1]  
ANNEGERS JF, 1981, CANCER, V48, P856, DOI 10.1002/1097-0142(19810801)48:3<856::AID-CNCR2820480332>3.0.CO
[2]  
2-4
[3]  
Announcements, 1989, Gynecologic Oncology, V35, P125, DOI [DOI 10.1016/0090-8258(89)90027-9, 10.1016/0090-8258(89)90027-9]
[4]  
[Anonymous], 1994, BLAUSTEINS PATHOLOGY, DOI [DOI 10.1007/978-1-4757-3889-6_12, 10.1007/978-1-4757-3889-6_12]
[5]  
BAILAR JC, 1963, CANCER, V16, P842, DOI 10.1002/1097-0142(196307)16:7<842::AID-CNCR2820160703>3.0.CO
[6]  
2-H
[7]   TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES [J].
BARAKAT, RR ;
WONG, G ;
CURTIN, JP ;
VLAMIS, V ;
HOSKINS, WJ .
GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :164-168
[8]  
DiSaia PJ, 1997, CLIN GYNECOLOGIC ONC, P134
[9]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[10]   ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537